CIPROCOPAN (NXP100) RECEIVES MARKETING APPROVAL IN CHINA FOR THE TREATMENT OF PATIENTS WITH PNH PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS

Reuters · 3d ago

Please log in to view news